Adaptive Biotechnologies vs LivaNova

Adaptive Biotechnologies (ADPT), health care, and LivaNova (LIVN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

LivaNova is worth $5.1B on the stock market and Adaptive Biotechnologies $4.6B: LivaNova is valued at 10% more. Adaptive Biotechnologies's operating margin in its latest fiscal year was -20.6% and LivaNova's 14.4%. Over the past year Adaptive Biotechnologies's share price has moved +103% and LivaNova's +71.5%.

Key facts

Adaptive Biotechnologies market value
$4.6B
LivaNova market value
$5.1B
LivaNova P/E
26.3
Adaptive Biotechnologies revenue
$277MFY to 2025-12-31
LivaNova revenue
$1.4BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Adaptive Biotechnologies vs LivaNova: every measure side by side
Measure Adaptive Biotechnologies LivaNova
SectorHealth CareHealth Care
Country United States United Kingdom
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.6Blower$5.1Bhigher
Revenue$277Mlower$1.4Bhigher
Earnings-$59.5Mhigher-$242.5Mlower
Employees624lower3,300higher
Total assets$512.7Mlower$2.6Bhigher
Valuation
P/E—26.3
P/S16.7higher3.6lower
P/B26.1—
Dividend yield0.00%—
Profitability
Operating margin-20.6%lower14.4%higher
Balance sheet
Net assets$218.8Mlower$1.2Bhigher
Total liabilities$287.7Mlower$1.4Bhigher
Total debt$131.2Mlower$376.7Mhigher
Cash on hand$70.5Mlower$635.6Mhigher
Price change
Today+2.22%higher-0.56%lower
1 year+103%higher+71.5%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Adaptive Biotechnologies only (3)

LivaNova only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns ADPT · Who owns LIVN

Further comparisons

Learn

Questions and answers

Which is bigger, Adaptive Biotechnologies or LivaNova?

By market value, LivaNova is the larger: $5.1B against $4.6B for Adaptive Biotechnologies. By revenue in its latest fiscal year, LivaNova is the larger: $1.4B against $277M for Adaptive Biotechnologies.

Which has the higher operating margin?

LivaNova: 14.4%, against -20.6% for Adaptive Biotechnologies. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

LivaNova: $376.7M, against $131.2M for Adaptive Biotechnologies. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Adaptive Biotechnologies and LivaNova?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Adaptive Biotechnologies and 1 holds LivaNova.

Cite this page

Funkfolio, “Adaptive Biotechnologies vs LivaNova”, data as of 18 November 2026. https://funkfolio.com/compare/adpt-vs-livn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.